KOSDAQHolding Companies221800

ZGOO Holdings

₩3,790▲ 2.43%2026-10-02 close

Market Cap

₩61.8B

Turnover

₩100M

Volume

40,000 shares

Shares out.

16.3M

PER

—

PBR

1.0×

EPS

-₩464

Dividend Yield

2.70%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩100 per share · Prices as of the 2026-10-02 close

Report overview

From Diagnostics to Venture Holdco: Growth vs. Profitability

Jigu Holdings has transformed from an in-vitro diagnostics and medical-IT firm into a venture holding company expanding into healthcare, AI, and consumer portfolios, but quarterly results remain in loss territory.

1
Through a spin-off in March 2026, the former U2Bio restructured into holding company Jigu Holdings, separating its diagnostics and medical-IT business into a newly spun-off U2Bio subsidiary.
2
The company has expanded its portfolio through acquisitions and investments spanning CRO (U2XLab, formerly SML Meditri), AI social entertainment (Neural Arcade), fashion (Hanger), and cosmetics (Tandem Studio).
3
Full-year 2025 revenue rose slightly to KRW 25.593 billion, but the company posted an operating loss of KRW 2.358 billion and a net loss of KRW 1.642 billion, extending its loss streak.
4
Second-quarter 2026 revenue surged to KRW 12.015 billion quarter-on-quarter, yet the net loss attributable to owners widened to KRW 3.698 billion.
5
On August 27, 2026, the CEO changed from Park Sang-wook to majority shareholder Lee Jae-woong, while a convertible bond issuance agenda item was also approved at an extraordinary shareholders' meeting.

Business structure

Through a spin-off in March 2026, Jigu Holdings separated its in-vitro diagnostics and medical-IT business into newly spun-off subsidiary U2Bio, while the parent transitioned into a venture investment and operating holding company.

U2Bio supplies in-vitro diagnostic testing services covering clinical chemistry, immunoserology, and molecular diagnostics, along with medical-IT solutions such as health-checkup and diagnostic-test platforms, personal health records, and cloud services for clinics and hospitals.

In January 2026, the company acquired an 84.34% stake in clinical sample analysis firm SML Meditri for KRW 6.3 billion, rebranding it as U2XLab and entering the new-drug clinical CRO market.

Concurrent with the spin-off, the company acquired AI social-entertainment startup Neural Arcade, formalizing a dual-track bio-and-AI strategy, and subsequently expanded into fashion company Hanger (43% stake) and cosmetics e-commerce firm Tandem Studio.

As of the second quarter of 2026, the healthcare segment (U2Bio and U2XLab) accounted for the majority of business-segment revenue, meaning diagnostics and clinical services remain the core cash-generating businesses for now.

Major shareholder and newly appointed CEO Lee Jae-woong, former CEO of Socar and Daum, together with founders such as Krafton chairman Chang Byung-gyu and Capyr Group chairman Kim Yo-han, form a founder group known as the "Jigu Alliance" that participates directly in management rather than passive investment.

Competitively, the domestic CRO market remains relatively fragmented with numerous small and mid-sized players, and the diagnostics/medical-IT space also features multiple network-based operators.

Earnings trend

Quarterly revenue · Operating profit

₩6.8B-₩200M25Q2₩6.9B-₩600M25Q3₩6.3B-₩900M25Q4₩7B-₩1.6B26Q1₩12B-₩500M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩69B₩15.7B2022₩30.8B-₩1.3B2023₩25B-₩3.1B2024₩25.6B-₩2.4B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩6.8B	-₩200M	−3.0%
2025Q3	₩6.9B	-₩600M	−8.5%
2025Q4	₩6.3B	-₩900M	−13.7%
2026Q1	₩7B	-₩1.6B	−22.8%
2026Q2	₩12B	-₩500M	−4.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩69B	₩15.7B	₩13.2B	22.8%	38.9%	50.8%
2023	₩30.8B	-₩1.3B	₩600M	−4.3%	1.7%	29.5%
2024	₩25B	-₩3.1B	-₩2.8B	−12.5%	−8.3%	30.7%
2025	₩25.6B	-₩2.4B	-₩1.6B	−9.2%	−3.9%	24.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05

Earnings analysis

Annual results show the company enjoyed a boom in 2022 with revenue of KRW 69.013 billion and operating profit of KRW 15.708 billion (22.8% operating margin), but revenue plunged to KRW 30.792 billion in 2023, flipping to an operating loss of KRW 1.338 billion.

In 2024, revenue fell further to KRW 25.040 billion, the operating loss widened to KRW 3.127 billion, and the net loss grew to KRW 2.840 billion. In 2025, revenue recovered modestly to KRW 25.593 billion, yet the operating loss of KRW 2.358 billion and net loss of KRW 1.642 billion kept the company in the red.

Operating margin moved from -4.3% in 2023 to -12.5% in 2024 and -9.2% in 2025, reflecting alternating improvement and deterioration.

On a quarterly basis, owners' net income briefly turned positive at KRW 0.031 billion in the second quarter of 2025, before reverting to losses of KRW 0.746 billion in the third quarter and KRW 0.679 billion in the fourth.

In the first quarter of 2026, revenue of KRW 6.983 billion came with a widened operating loss of KRW 1.595 billion but a relatively smaller net loss of KRW 0.285 billion; in the second quarter, revenue jumped to KRW 12.015 billion quarter-on-quarter and the operating loss narrowed to KRW 0.549 billion, yet the owners' net loss expanded sharply to KRW 3.698 billion.

This growing divergence between operating and net results suggests the possible influence of one-off items tied to newly consolidated subsidiaries or non-operating factors such as equity-method or valuation losses.

Operating cash flow showed a narrowing outflow trend, from -KRW 2.555 billion in 2023 to -KRW 1.731 billion in 2024 and -KRW 1.562 billion in 2025.

Industry analysis

The global CRO (contract research organization) market is estimated at roughly USD 92.98 billion in 2026, with an approximately 8% CAGR projected through 2031, and the domestic Korean CRO market has reportedly grown faster than the global market over the past five years.

Outside a handful of leading firms, the domestic CRO industry remains a relatively fragmented market with numerous small and mid-sized players, leaving room for specialized niche operators.

Research also indicates that CRO revenue from biotech clients has been growing faster than revenue from large pharmaceutical companies, suggesting that outsourcing demand from smaller biotech and pharma firms is a key growth driver for the broader CRO industry.

In diagnostics and medical IT, competition continues to center on clinic and hospital networks, and Jigu Holdings participates in this market through U2Bio's network of roughly 2,000 medical institutions.

Meanwhile, the AI social-entertainment, fashion, and cosmetics businesses the company is pursuing outside healthcare belong to industries with different cycles and competitive dynamics than healthcare and CRO, making it harder to assess the overall portfolio's earnings structure.

This diversified holding-company model, in which a founder alliance directly participates in management across multiple industries, positions the company differently from conventional holding companies or venture capital firms.

Outlook

The company's next regular earnings disclosure will be the third-quarter 2026 report, with a statutory filing deadline of November 16, 2026 under the Capital Markets Act.

In an August 2026 IR presentation, the company reportedly stated it would prioritize improving segment profitability and cash generation in the second half of the year.

The same material indicated that second-quarter adjusted EBITDA for the business segment improved to KRW 0.61 billion from a first-quarter loss of KRW 1.32 billion; note this is a preliminary IR-sourced metric distinct from the confirmed operating loss figures disclosed to DART.

At the June 2026 extraordinary shareholders' meeting, agenda items including approval of convertible bond issuance and separation of the board chair and CEO roles were passed, and the actual timing and scale of any convertible bond issuance remains a variable affecting future capital structure.

Following Lee Jae-woong's appointment as CEO on August 27, with management now centered around the founder group, the concrete management strategy and resource allocation direction under the new leadership also warrant monitoring.

The timing and impact of newly consolidated subsidiaries such as Hanger (fashion), Neural Arcade (AI social entertainment), and Tandem Studio (cosmetics) being fully reflected in consolidated results is another point to watch.

A corporate value-up plan was voluntarily disclosed in May 2026, and any subsequent disclosure of its concrete implementation could offer reference points on governance and shareholder-return direction.

Valuation

PER

—

PBR

1.0×

ROE

-12.8%

EPS

-₩464

BPS

₩3,632

Dividend per share

₩100

Because of the accumulated net losses over the most recent four quarters, calculating a price-to-earnings ratio is difficult, limiting earnings-based valuation comparisons.

In terms of price-to-book, the stock trades at a level close to its most recently disclosed book value per share, without a clearly pronounced premium or discount relative to net assets. On the dividend side, the company maintains a modest cash dividend, though the yield is assessed as below the industry average.

Since profitability turned negative after 2022 and losses persisted through 2025, recent quarters have shown larger revenue scale alongside greater volatility in net results, meaning the timing and durability of any earnings recovery will require confirmation through future quarterly results.

In addition, the recent increase in listed shares via third-party allotment capital raising is a factor to consider when interpreting per-share metrics.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05

Bull factors

Diversified Venture Portfolio

Jigu Holdings is pursuing a strategy of reducing single-business dependence by adding heterogeneous industries such as AI social entertainment, fashion, and cosmetics to its diagnostics- and CRO-centered healthcare business.

The acquisition of SML Meditri (now U2XLab) brought entry into the growing new-drug clinical CRO segment, and further investments in Neural Arcade, Hanger, and Tandem Studio broadened the portfolio base.

A multi-industry investment portfolio can offer structural benefits in diversifying impact when any single sector faces a downturn.

Direct Management Involvement by Founder Alliance

Former Socar and Daum CEO Lee Jae-woong, holding a 20.36% stake as majority shareholder, has taken direct management control as CEO, while founders of the 'Jigu Alliance' such as Krafton chairman Chang Byung-gyu participate as in-house directors in decision-making.

The group has stated it pursues long-term operational involvement, distinct from typical venture capital funds seeking fund-maturity exits. The alignment between management and controlling shareholder stakes is a factor worth noting for shareholder interest alignment.

Signs of Profitability Improvement in Healthcare Segment

According to company IR materials released in August 2026, second-quarter adjusted EBITDA for the business segment reportedly improved to KRW 0.61 billion from a first-quarter loss.

The same material indicated the healthcare segment (U2Bio and U2XLab) accounted for the majority of segment revenue, suggesting that recovery in the core business's cash generation could meaningfully affect overall results.

However, this should be considered alongside the fact that it is a preliminary, supplementary metric separate from the confirmed operating income figures.

Bear factors

Persistent Losses and Net Income Volatility

The company posted operating losses in three consecutive years from 2023 through 2025, and in the second quarter of 2026, despite a large revenue increase, the net loss attributable to owners widened to KRW 3.698 billion.

The growing gap between operating and net results suggests increasing influence from non-operating factors, raising questions about earnings quality. Given the high quarter-to-quarter volatility in results, it remains premature to conclude a sustained profitability recovery.

Frequent Capital Raises and Management Turnover

Multiple third-party allotment rights offerings occurred in 2026, increasing the number of listed shares, and convertible bond issuance has also been approved at an extraordinary shareholders' meeting.

The CEO has also changed twice in 2026, in March and August, which, while potentially inherent to business restructuring, is a factor to monitor for governance stability. The possibility of repeated share dilution is a consideration for existing shareholders.

Integration Risk from Heterogeneous Diversification

Expansion into AI social entertainment, fashion, and cosmetics—industries unrelated to healthcare and CRO—means that each business has different cycles and competitive environments, making management's resource allocation capability and inter-business synergy realization important variables.

Since the newly consolidated subsidiaries' earnings have not yet been fully reflected in consolidated results, there is a time lag before their actual earnings contribution can be confirmed. There is also a possibility that excessive diversification could dilute focus on core businesses.

Risk factors

Financial Structure and Cash Flow

Operating cash flow was negative for three consecutive years from 2023 through 2025, and although the outflow has narrowed, cash generation has not yet been achieved.

With losses persisting, the structure of relying on external funding (rights offerings, convertible bonds) for new investments and acquisitions could lead to further dilution or financing cost burdens.

The debt ratio declined from 50.8% in 2022 to 24.1% in 2025, but this figure also reflects the impact of capital raises and should be interpreted with that context in mind.

Business Diversification and Integration

Investments across numerous heterogeneous sectors—CRO, AI social entertainment, fashion, and cosmetics—within a short period could increase the burden on management's oversight capacity. If synergies among subsidiaries fail to materialize as expected, this could lead to reduced returns relative to investment.

The financial soundness of newly consolidated entities and their linkage to existing businesses also require ongoing monitoring.

Governance and Shareholder Structure

The CEO changed twice within 2026, and the structure shifted to one where the majority shareholder directly serves as CEO.

With the founder coalition 'Jigu Alliance' holding a substantial portion of shares, the fairness and transparency of future capital-raising processes, including selection of third-party allotment targets, could remain a point of ongoing attention.

Minority shareholders need to weigh both the advantages and disadvantages of a decision-making structure centered on the controlling shareholder.

What to watch next

By November 16, 2026
Statutory filing deadline for the third-quarter 2026 report, a point to check revenue and operating income trends and whether newly consolidated subsidiaries are reflected.
During the fourth quarter of 2026
Worth checking whether the convertible bonds approved at the June extraordinary shareholders' meeting are actually issued, and at what size and terms, to assess changes in capital structure.
During the fourth quarter of 2026
Concrete management strategy and resource allocation direction expected to be disclosed under new CEO Lee Jae-woong's leadership, and whether the adjusted EBITDA improvement trend continues into the third quarter, should be monitored.
Fourth quarter 2026 through early 2027
Need to monitor when and how the earnings of recently consolidated subsidiaries such as Hanger, Neural Arcade, and Tandem Studio are fully reflected in consolidated results, and their contribution.

Overall view

Jigu Holdings is rapidly restructuring from a single-business diagnostics and medical-IT company into a venture holding company spanning CRO, AI social entertainment, fashion, and cosmetics, while building a distinctive governance model in which a founder coalition led by Lee Jae-woong participates directly in management.

Financially, following strong profitability in 2022, the company posted operating losses for three consecutive years from 2023 through 2025, and in 2026, while revenue scale has grown, quarterly net income volatility has also widened.

Signs of adjusted profitability improvement in the healthcare segment and a diversified portfolio can be cited as positive factors, but frequent rights offerings, CEO turnover, and integration risk across heterogeneous businesses warrant balanced attention.

Key variables going forward include the November 16, 2026 filing deadline for the next quarterly report, whether convertible bonds are actually issued, and the timing of newly consolidated subsidiaries' earnings being reflected in results.

With valuation calculation constrained by ongoing losses and the stock trading near book value, further disclosure confirmation on earnings quality and sustainability appears warranted.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-10-02 · Data as of 2026-10-01

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.